Trial Profile
Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib After Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma (BMT CTN 1302)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2022
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Bortezomib; Fludarabine; Melphalan; Methotrexate; Tacrolimus
- Indications Graft-versus-host disease; Multiple myeloma
- Focus Therapeutic Use
- Acronyms BMT CTN 1302
- 22 Dec 2021 Status changed from active, no longer recruiting to completed.
- 08 Jun 2021 Results assessing efficacy and safety of maintenance ixazomib after allogeneic hematopoietic cell transplantation for high-risk multiple myeloma, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 03 Oct 2018 Status changed from recruiting to active, no longer recruiting.